189 related articles for article (PubMed ID: 32658035)
21. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole.
Eggert K; Öhlwein C; Kassubek J; Wolz M; Kupsch A; Ceballos-Baumann A; Ehret R; Polzer U; Klostermann F; Schwarz J; Fuchs G; Jost W; Albert A; Haag A; Hermsen A; Lohmüller K; Kuhn K; Wangemann M; Oertel WH;
Clin Neuropharmacol; 2014; 37(4):116-22. PubMed ID: 24992083
[TBL] [Abstract][Full Text] [Related]
22. Piribedil-induced sleep attacks in Parkinson's disease.
Tan EK
Fundam Clin Pharmacol; 2003 Feb; 17(1):117-9. PubMed ID: 12588638
[TBL] [Abstract][Full Text] [Related]
23. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study.
Li W; Zhang H; Zhang Y; Wang K; Hui J; Yi Z
CNS Neurosci Ther; 2024 Apr; 30(4):e14531. PubMed ID: 37983933
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Etminan M; Gill S; Samii A
Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
[TBL] [Abstract][Full Text] [Related]
26. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
Guttman M
Neurology; 1997 Oct; 49(4):1060-5. PubMed ID: 9339690
[TBL] [Abstract][Full Text] [Related]
27. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
28. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
Pilipovich AA; Golubev VL
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
[TBL] [Abstract][Full Text] [Related]
29. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
32. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.
Perez-Lloret S; Rascol O
CNS Drugs; 2016 Aug; 30(8):703-17. PubMed ID: 27344665
[TBL] [Abstract][Full Text] [Related]
33. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis.
Li T; Zou S; Zhang Z; Liu M; Liang Z
BMC Neurol; 2022 Aug; 22(1):320. PubMed ID: 36008796
[TBL] [Abstract][Full Text] [Related]
35. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
36. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.
Zhou CQ; Zhang JW; Wang M; Peng GG
J Clin Neurosci; 2014 Jul; 21(7):1094-101. PubMed ID: 24786715
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Pinter MM; Pogarell O; Oertel WH
J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
[TBL] [Abstract][Full Text] [Related]
38. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
[TBL] [Abstract][Full Text] [Related]
39. [The use of piribedil in early and late stages of Parkinson's disease].
Fedorova NV; Kulua TK; Gubanova ЕN
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(10):96-98. PubMed ID: 26525631
[TBL] [Abstract][Full Text] [Related]
40. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
